Human immunodeficiency virus and type 2 diabetes

The prevalence of diabetes is higher amongst individuals infected with HIV. The major contributor to hyperglycaemia is thought to be iatrogenic, with protease inhibitors being most commonly associated to insulin resistance. This article is to update general practitioners on the diagnosis and managem...

Descripción completa

Detalles Bibliográficos
Autores principales: Avari, P., Devendra, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Case Study (Individual)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434564/
https://www.ncbi.nlm.nih.gov/pubmed/28539977
http://dx.doi.org/10.1080/17571472.2017.1302872
_version_ 1783237071525117952
author Avari, P.
Devendra, S.
author_facet Avari, P.
Devendra, S.
author_sort Avari, P.
collection PubMed
description The prevalence of diabetes is higher amongst individuals infected with HIV. The major contributor to hyperglycaemia is thought to be iatrogenic, with protease inhibitors being most commonly associated to insulin resistance. This article is to update general practitioners on the diagnosis and management of diabetes in HIV-infected patients. Specific considerations are highlighted including interactions of particular diabetic drugs with antiretroviral therapy (ART). We articulate why the use of Hemoglobin A1c (HbA1c) testing is not recommended as a diagnostic tool.
format Online
Article
Text
id pubmed-5434564
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-54345642017-05-24 Human immunodeficiency virus and type 2 diabetes Avari, P. Devendra, S. London J Prim Care (Abingdon) Case Study (Individual) The prevalence of diabetes is higher amongst individuals infected with HIV. The major contributor to hyperglycaemia is thought to be iatrogenic, with protease inhibitors being most commonly associated to insulin resistance. This article is to update general practitioners on the diagnosis and management of diabetes in HIV-infected patients. Specific considerations are highlighted including interactions of particular diabetic drugs with antiretroviral therapy (ART). We articulate why the use of Hemoglobin A1c (HbA1c) testing is not recommended as a diagnostic tool. Taylor & Francis 2017-03-19 /pmc/articles/PMC5434564/ /pubmed/28539977 http://dx.doi.org/10.1080/17571472.2017.1302872 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Study (Individual)
Avari, P.
Devendra, S.
Human immunodeficiency virus and type 2 diabetes
title Human immunodeficiency virus and type 2 diabetes
title_full Human immunodeficiency virus and type 2 diabetes
title_fullStr Human immunodeficiency virus and type 2 diabetes
title_full_unstemmed Human immunodeficiency virus and type 2 diabetes
title_short Human immunodeficiency virus and type 2 diabetes
title_sort human immunodeficiency virus and type 2 diabetes
topic Case Study (Individual)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434564/
https://www.ncbi.nlm.nih.gov/pubmed/28539977
http://dx.doi.org/10.1080/17571472.2017.1302872
work_keys_str_mv AT avarip humanimmunodeficiencyvirusandtype2diabetes
AT devendras humanimmunodeficiencyvirusandtype2diabetes

Ejemplares similares